Goldman Sachs Raises Iovance Price Target to $2 as Amtagvi Delivers 44% ORR
Goldman Sachs lifted Iovance price target to $2 from $1.50 on February 5, retaining a Sell rating. Real-world data in 41 advanced melanoma patients of commercial Amtagvi showed 44% ORR and 73% disease control, underscoring its best-in-class profile as the first FDA-approved one-time T-cell therapy for solid tumors.
1. Goldman Sachs Price Target Revision
Goldman Sachs raised Iovance Biotherapeutics’ price target to $2 from $1.50 on February 5 while maintaining its Sell rating, reflecting cautious optimism about the stock’s upside potential despite lingering uncertainties.
2. Real-World Amtagvi Data
A retrospective real-world study in 41 advanced melanoma patients treated with commercial Amtagvi reported a 44% objective response rate and 73% disease control rate, highlighting enhanced outcomes with earlier treatment and reinforcing Amtagvi’s best-in-class profile.
3. Implications for Stock Performance
Positive clinical data and hedge fund interest could attract new investors to Iovance, but the Sell rating and modest target increase suggest analysts remain wary of wider adoption risks and competitive pressures in the immunotherapy landscape.